Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients with High-risk Stage I or Stage II Endometrial Cancer

Article

This clinical trial is studying whether pelvic radiation therapy is more effective than vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with endometrial cancer.

Study Type: Interventional

Age/Sex Requirements: 18 years+ (female)

Sponsor: Gynecologic Oncology Group

Purpose: This clinical trial is studying whether pelvic radiation therapy is more effective than vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with endometrial cancer. The primary outcome measure of the study will be duration of recurrence-free survival, with secondary measures including duration of overall survival; incidences of vaginal, pelvic, or distant recurrence; death from endometrial cancer; toxicity; and quality of life.

Click here to learn more about this clinical trial.

Related Videos
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
3 KOLs are featured in this program.
3 KOLs are featured in this program.
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
A panel of 4 experts on HIV
A panel of 4 experts on HIV
Edward V Loftus, Jr, MD | Credit: Mayo Clinic
A panel of 4 experts on asthma
A panel of 4 experts on asthma
Katie Ross-Driscoll, PhD, MPH | Credit: Regenstrief Institute
© 2024 MJH Life Sciences

All rights reserved.